| MeSH term | MeSH ID | Detail |
|---|---|---|
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Albano L et al. | OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. | 2013 | Transplantation | pmid:23982340 |
| Therapondos G et al. | Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? | 2003 | Transplantation | pmid:12883220 |
| Marcos A et al. | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. | 2004 | Transplantation | pmid:15480160 |
| Gruessner RW et al. | A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. | 1995 | Transplantation | pmid:7530871 |
| Jindal RM et al. | Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. | 1994 | Transplantation | pmid:7514317 |
| Boleslawski E et al. | Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. | 2004 | Transplantation | pmid:15223897 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Bilolo KK et al. | Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. | 2003 | Transplantation | pmid:12811249 |
| Miyakoshi S et al. | Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. | 2007 | Transplantation | pmid:17700155 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
| Fisher RA et al. | A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9884248 |
| Yanchar NL et al. | Tacrolimus (FK506)--its effects on intestinal glucose transport. | 1996 | Transplantation | pmid:8610392 |
| Solez K et al. | Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9884269 |
| Johansson A and Möller E | Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. | 1990 | Transplantation | pmid:1701570 |
| Reyes J et al. | Expressive dysphasia possibly related to FK506 in two liver transplant recipients. | 1990 | Transplantation | pmid:1701571 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
| Theruvath TP et al. | Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. | 2001 | Transplantation | pmid:11468538 |
| Kung L and Halloran PF | Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. | 2000 | Transplantation | pmid:10933159 |
| Beatty PR et al. | Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. | 1998 | Transplantation | pmid:9603175 |
| Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
| Zervos XA et al. | Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. | 1998 | Transplantation | pmid:9583863 |
| Maes BD et al. | Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. | 1999 | Transplantation | pmid:10589943 |
| Mehra MR et al. | Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. | 2002 | Transplantation | pmid:12490790 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Woodle ES et al. | FK506: inhibition of humoral mechanisms of hepatic allograft rejection. | 1992 | Transplantation | pmid:1379749 |
| Dean PG et al. | Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. | 2008 | Transplantation | pmid:18431244 |
| Shoji T et al. | Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. | 2007 | Transplantation | pmid:18091523 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Przepiorka D et al. | Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. | 1996 | Transplantation | pmid:8990368 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |